Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 59, Issue 2, 2017, Pages 753-762

  Cacciamani, Federica ^a   Tandetnik, Caroline ^a,b   Gagliardi, Geoffroy ^a   Bertin, Hugo ^a,c   Habert, Marie Odile ^a,c   Hampel, Harald ^a,d   Boukadida, Laurie ^a   Révillon, Marie ^a   Epelbaum, Stéphane ^a,d   Dubois, Bruno ^a,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CATI Multicenter Neuroimaging Platform   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Alzheimer's disease; awareness; biomarkers; cognitive complaints; subjective cognitive decline

Indexed keywords

AMYLOID PROTEIN; BIOLOGICAL MARKER; FLORBETAPIR F 18; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGED; ALZHEIMER DISEASE; ARTICLE; ASYMPTOMATIC DISEASE; AWARENESS; BRAIN ATROPHY; BRAIN CORTEX; BRAIN METABOLISM; BRAIN SIZE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DEMOGRAPHY; DISEASE MARKER; FEMALE; GERIATRIC DEPRESSION SCALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MOLECULAR PATHOLOGY; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY; PATIENT AUTONOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; STATE TRAIT ANXIETY INVENTORY; TASK PERFORMANCE; TRAIL MAKING TEST; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; COMPLICATION; DIAGNOSTIC IMAGING; HEMISPHERIC DOMINANCE; METABOLISM; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUESTIONNAIRE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; AWARENESS; BRAIN; BRAIN MAPPING; COGNITIVE DYSFUNCTION; ETHYLENE GLYCOLS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; SURVEYS AND QUESTIONNAIRES;

EID: 85024928653     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170399     Document Type: Article

References (40)

1. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M, Subjective Cognitive Decline Initiative (SCD-I) Working, Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10, 844-852.
2. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B (2014) Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr Scand 130, 439-451.
3. Zlatar ZZ, Moore RC, Palmer BW, Thompson WK, Jeste DV (2014) Cognitive complaints correlate with depression rather than concurrent objective cognitive impairment in the successful aging evaluation baseline sample. J Geriatr Psychiatry Neurol 27, 181-187.
4. Merema MR, Speelman CP, Foster JK, Kaczmarek EA (2013) Neuroticism (not depressive symptoms) predicts memory complaints in some community-dwelling older adults. Am J Geriatr Psychiatry 21, 729-736.
5. Tardy M, Gonthier R, Barthelemy JC, Roche F, Crawford-Achour E (2015) Subjective sleep and cognitive complaints in 65 year old subjects: A significant association. The PROOF cohort. J Nutr Health Aging 19, 424-430.
6. Ponds RW, Commissaris KJ, Jolles J (1997) Prevalence and covariates of subjective forgetfulness in a normal population in The Netherlands. Int J Aging Hum Dev 45, 207-221.
7. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9, 63-75.e2.
8. Cacchione PZ, Powlishta KK, Grant EA, Buckles VD, Morris JC (2003) Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. J Am Geriatr Soc 51, 819-823.
9. Carr DB, Gray S, Baty J, Morris JC (2000) The value of informant versus individual's complaints of memory impairment in early dementia. Neurology 55, 1724-1726.
10. Orfei MD, Varsi AE, Blundo C, Celia E, Casini AR, Caltagirone C, Spalletta G (2010) Anosognosia in mild cognitive impairment and mild Alzheimer's disease: Frequency and neuropsychological correlates. Am J Geriatr Psychiatry 18, 1133-1140.
11. Michon A, Deweer B, Pillon B, Agid Y, Dubois B (1994) Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry 57, 805-809.
12. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr (2016) Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD", July 23 2, Washington DC U, Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 12, 292-323.
13. Amieva H, Carcaillon L, Rouze L'Alzit-Schuermans P, Millet X, Dartigues JF, Fabrigoule C (2007) Cued and uncued memory tests: Norms in elderly adults from the 3 Cities epidemiological study. Rev Neurol (Paris) 163, 205-221.
14. Monahan PO, Alder CA, Khan BA, Stump T, Boustani MA (2014) The Healthy Aging Brain Care (HABC) Monitor: Validation of the Patient Self-Report Version of the clinical tool designed to measure and monitor cognitive, functional, and psychological health. Clin Interv Aging 9, 2123-2132.
15. Monahan PO, Boustani MA, Alder C, Galvin JE, Perkins AJ, Healey P, Chehresa A, Shepard P, Bubp C, Frame A, Callahan C (2012) Practical clinical tool to monitor dementia symptoms: The HABC-Monitor. Clin Interv Aging 7, 143-157.
16. McNair D, Kahn R (1983) Self-assessment of cognitive deficits. In Assessment in Geriatric Psychopharmacology, Crook T, Ferris A, Baltus R eds. Mark Powley Associates, New Canaan, CT, pp. 137-143.
17. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12, 233-239.
18. Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G (1983) Manual for the state-trait anxiety inventory (form Y). Consulting Psychologists Press, Palo Alto.
19. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17, 37-49.
20. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K (1996) Assessment of activities of daily living in dementia: Development of the Bristol Activities of Daily Living Scale. Age Ageing 25, 113-120.
21. Brooks R (1996) EuroQol: The current state of play. Health Policy 37, 53-72.
22. Lim YY, Snyder PJ, Pietrzak RH, Ukiqi A, Villemagne VL, Ames D, Salvado O, Bourgeat P, Martins RN, Masters CL, Rowe CC, Maruff P (2015) Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement (Amst) 2, 19-26.
23. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS, Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing, Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Cooperative Study (2014) The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol 71, 961-970.
24. LimYY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Research AIBL, Group (2014) Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137, 221-231.
25. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, AV45-A07 Study, Group (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
26. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
27. Besson FL, La Joie R, Doeuvre L, Gaubert M, Mezenge F, Egret S, Landeau B, Barre L, Abbas A, Ibazizene M, de La Sayette V, Desgranges B, Eustache F, Chetelat G (2015) Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J Neurosci 35, 10402-10411.
28. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877.
29. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
30. Kim H, Chupin M, Colliot O, Bernhardt BC, Bernasconi N, Bernasconi A (2012) Automatic hippocampal segmentation in temporal lobe epilepsy: Impact of developmental abnormalities. Neuroimage 59, 3178-3186.
31. Rolls ET, Joliot M, Tzourio-Mazoyer N (2015) Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas. Neuroimage 122, 1-5.
32. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Alzheimer's Disease Neuroimaging, Initiative (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
33. Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, Buckley RF, Chetelat G, Dubois B, Ellis KA, Gifford KA, Jefferson AL, Jessen F, Katz MJ, Lipton RB, Luck T, Maruff P, Mielke MM, Molinuevo JL, Naeem F, Perrotin A, Petersen RC, Rami L, Reisberg B, Rentz DM, Riedel-Heller SG, Risacher SL, Rodriguez O, Sachdev PS, Saykin AJ, Slavin MJ, Snitz BE, Sperling RA, Tandetnik C, van der Flier WM, Wagner M, Wolfsgruber S, Sikkes SA (2015) Subjective cognitive decline in older adults: An overview of self-report measures used across 19 international research studies. J Alzheimers Dis 48(Suppl 1), S63-S86.
34. Glodzik-Sobanska L, Reisberg B, De Santi S, Babb JS, Pirraglia E, Rich KE, Brys M, de Leon MJ (2007) Subjective memory complaints: Presence, severity and future outcome in normal older subjects. Dement Geriatr Cogn Disord 24, 177-184.
35. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
36. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
37. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006)[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452.
38. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
39. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
40. Starkstein SE (2014) Anosognosia in Alzheimer's disease: Diagnosis, frequency, mechanism and clinical correlates. Cortex 61, 64-73.